Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, Cali AMG, Sieber J, Stella P, Wang X, Frías JP, Roussel R, Bolli GB. Rosenstock J, et al. Among authors: cali amg. Diabetes Care. 2018 Oct;41(10):2147-2154. doi: 10.2337/dc18-0559. Epub 2018 Aug 13. Diabetes Care. 2018. PMID: 30104294 Clinical Trial.
Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment.
Javier Escalada F, Halimi S, Senior PA, Bonnemaire M, Cali AMG, Melas-Melt L, Karalliedde J, Ritzel RA. Javier Escalada F, et al. Among authors: cali amg. Diabetes Obes Metab. 2018 Dec;20(12):2860-2868. doi: 10.1111/dom.13470. Epub 2018 Aug 30. Diabetes Obes Metab. 2018. PMID: 30003642 Free PMC article.
Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
Roussel R, d'Emden MC, Fisher M, Ampudia-Blasco FJ, Stella P, Bizet F, Cali AMG, Wysham CH. Roussel R, et al. Diabetes Obes Metab. 2018 Feb;20(2):448-452. doi: 10.1111/dom.13071. Epub 2017 Sep 14. Diabetes Obes Metab. 2018. PMID: 28736942 Free PMC article. Clinical Trial.
A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen.
Bolli GB, Wysham C, Fisher M, Chevalier S, Cali AMG, Leroy B, Riddle MC. Bolli GB, et al. Diabetes Obes Metab. 2019 Feb;21(2):402-407. doi: 10.1111/dom.13515. Epub 2018 Oct 2. Diabetes Obes Metab. 2019. PMID: 30160030 Free PMC article.
The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.
Meneghini LF, Mauricio D, Orsi E, Lalic NM, Cali AMG, Westerbacka J, Stella P, Candelas Dea C, Pilorget V, Perfetti R, Khunti K; DUNE investigators. Meneghini LF, et al. Diabetes Obes Metab. 2019 Jun;21(6):1429-1436. doi: 10.1111/dom.13673. Epub 2019 Mar 28. Diabetes Obes Metab. 2019. PMID: 30768845 Free PMC article.
Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
Gupta S, Wang H, Skolnik N, Tong L, Liebert RM, Lee LK, Stella P, Cali A, Preblick R. Gupta S, et al. Among authors: cali a. Adv Ther. 2018 Jan;35(1):43-55. doi: 10.1007/s12325-017-0651-3. Epub 2018 Jan 8. Adv Ther. 2018. PMID: 29313285 Free PMC article.
217 results